Regeneron Pharmaceuticals Inc. and AstraZeneca today announced that the companies entered into a collaboration to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.

Metabolic comorbidities, including obesity and type 2 diabetes increase the risk of morbidity and mortality in patients who contract coronavirus disease 2019 (Covid-19). But findings published in the journal Nature show that not only are patients with diabetes more at risk of more severe outcomes, patients without diabetes who develop Covid-19 may also be at a higher risk of actually developing diabetes following recovery. 

Clarus Therapeutics Inc. and Blue Water Acquisition Corp. on April 27 announced a definitive business combination agreement that will result in Clarus becoming a publicly traded company. 

liver

Results of Viking Therapeutics’ metabolic disease program exceed all other oral therapies in development in terms of reducing liver fat for nonalcoholic steatohepatitis (NASH) patients, according to Greg Zante, the company’s SVP of finance.